Symbols / GALT
GALT Chart
About
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 203.75M |
| Enterprise Value | 320.48M | Income | -37.44M | Sales | — |
| Book/sh | -1.95 | Cash/sh | 0.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -1.88 | PEG | — |
| P/S | — | P/B | -1.62 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.08 |
| Current Ratio | 0.09 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.59 | EPS next Y | -1.68 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 07:00 | ROA | -87.09% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 64.47M |
| Shs Float | 45.75M | Short Float | 10.53% | Short Ratio | 11.57 |
| Short Interest | — | 52W High | 7.13 | 52W Low | 1.12 |
| Beta | 0.99 | Avg Volume | 489.21K | Volume | 214.22K |
| Target Price | $11.00 | Recom | None | Prev Close | $3.03 |
| Price | $3.16 | Change | 4.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$3.16
Latest analyst target
3. DCF / Fair value
$-6.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.16
Low
$11.00
High
$11.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-04-02 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-27 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-04-09 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-03-03 | reit | HC Wainwright & Co. | — → Buy | $11 |
| 2022-05-17 | main | HC Wainwright & Co. | — → Buy | $11 |
| 2021-04-16 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2020-08-13 | main | HC Wainwright & Co. | — → Buy | $12 |
| 2020-04-03 | main | B. Riley Securities | — → Buy | $4 |
| 2020-03-17 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2019-02-13 | init | B. Riley Securities | — → Buy | $11 |
| 2017-10-19 | init | Roth Capital | — → Buy | $8 |
| 2017-10-06 | init | Seaport Global | — → Buy | $5 |
| 2017-03-30 | up | HC Wainwright & Co. | Neutral → Buy | $4 |
- Why Did GALT Shares Plummet Over 30% Today? - Stocktwits Fri, 19 Dec 2025 08
- Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha Wed, 26 Nov 2025 08
- $GALT stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 10 Dec 2025 08
- 10x fund sells Galectin Therapeutics (GALT) shares worth $920,855 - Investing.com Mon, 08 Dec 2025 08
- Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials - Yahoo Finance ue, 23 Sep 2025 07
- GALT: HC Wainwright & Co. Raises Price Target to $11, Maintains Buy Rating | GALT Stock News - GuruFocus Wed, 17 Dec 2025 08
- Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know - Nasdaq Fri, 12 Sep 2025 07
- $GALT stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 10 Nov 2025 08
- 10x fund sells Galectin therapeutics (GALT) shares worth $851,700 - Investing.com hu, 04 Dec 2025 08
- MODD, GALT, XCUR, PEPG, BSGM Stocks Pop After Hours On Clinical Updates And Strategic Moves - Nasdaq Fri, 12 Sep 2025 07
- Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha Wed, 24 Dec 2025 08
- $GALT stock is down 36% today. Here's what we see in our data. - Quiver Quantitative Fri, 19 Dec 2025 08
- Freeman buys Galectin therapeutics (GALT) stock worth $14,495 - Investing.com Fri, 18 Jul 2025 07
- Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data (NASDAQ:GALT) - Seeking Alpha hu, 04 Dec 2025 08
- $GALT stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Mon, 18 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 300 | 810.0 | — | Purchase at price 2.70 per share. | ELDRED KARY N. | Director | — | 2026-02-06 00:00:00 | D |
| 1 | 13158 | 40000.0 | — | Stock Award(Grant) at price 3.04 per share. | UIHLEIN RICHARD E | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-16 00:00:00 | D |
| 2 | 60000 | 232402.0 | — | Sale at price 3.65 - 4.20 per share. | JAMIL KHURRAM | Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 60000 | 233388.0 | — | Sale at price 3.67 - 4.20 per share. | CALLICUTT JACK W | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 4 | 84000 | 321134.0 | — | Sale at price 3.58 - 4.20 per share. | LEWIS JOEL | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 5 | 60000 | nan | — | — | JAMIL KHURRAM | Officer | — | 2026-01-02 00:00:00 | D |
| 6 | 60000 | nan | — | — | CALLICUTT JACK W | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 7 | 84000 | nan | — | — | LEWIS JOEL | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 8 | 8125 | 33089.0 | — | Sale at price 4.07 per share. | JAMIL KHURRAM | Officer | — | 2025-12-31 00:00:00 | D |
| 9 | 8125 | 9994.0 | — | Conversion of Exercise of derivative security at price 1.23 per share. | JAMIL KHURRAM | Officer | — | 2025-12-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -42.06M | -37.81M | -38.27M | -30.14M |
| TotalUnusualItems | 588.00K | -432.00K | 557.00K | 138.00K |
| TotalUnusualItemsExcludingGoodwill | 588.00K | -432.00K | 557.00K | 138.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -47.05M | -41.07M | -38.78M | -30.53M |
| ReconciledDepreciation | 37.00K | 33.00K | 32.00K | 41.00K |
| EBITDA | -41.47M | -38.24M | -37.71M | -30.00M |
| EBIT | -41.51M | -38.27M | -37.74M | -30.04M |
| NetInterestIncome | -5.20M | -2.56M | -981.00K | -486.00K |
| InterestExpense | 5.54M | 2.79M | 1.03M | 489.00K |
| InterestIncome | 338.00K | 230.00K | 52.00K | 3.00K |
| NormalizedIncome | -47.63M | -40.63M | -39.33M | -30.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -47.05M | -41.07M | -38.78M | -30.53M |
| TotalExpenses | 42.43M | 38.07M | 38.35M | 30.18M |
| TotalOperatingIncomeAsReported | -42.43M | -38.07M | -38.35M | -30.18M |
| DilutedAverageShares | 62.31M | 60.16M | 59.39M | 58.53M |
| BasicAverageShares | 62.31M | 60.16M | 59.39M | 58.53M |
| DilutedEPS | -0.76 | -0.74 | -0.65 | -0.52 |
| BasicEPS | -0.76 | -0.74 | -0.65 | -0.52 |
| DilutedNIAvailtoComStockholders | -47.20M | -44.80M | -38.87M | -30.70M |
| NetIncomeCommonStockholders | -47.20M | -44.80M | -38.87M | -30.70M |
| OtherunderPreferredStockDividend | 0.00 | 3.62M | 0.00 | |
| PreferredStockDividends | 153.00K | 120.00K | 97.00K | 171.00K |
| NetIncome | -47.05M | -41.07M | -38.78M | -30.53M |
| NetIncomeIncludingNoncontrollingInterests | -47.05M | -41.07M | -38.78M | -30.53M |
| NetIncomeContinuousOperations | -47.05M | -41.07M | -38.78M | -30.53M |
| PretaxIncome | -47.05M | -41.07M | -38.78M | -30.53M |
| OtherIncomeExpense | 588.00K | -432.00K | 557.00K | 138.00K |
| GainOnSaleOfSecurity | 588.00K | -432.00K | 557.00K | 138.00K |
| NetNonOperatingInterestIncomeExpense | -5.20M | -2.56M | -981.00K | -486.00K |
| InterestExpenseNonOperating | 5.54M | 2.79M | 1.03M | 489.00K |
| InterestIncomeNonOperating | 338.00K | 230.00K | 52.00K | 3.00K |
| OperatingIncome | -42.43M | -38.07M | -38.35M | -30.18M |
| OperatingExpense | 42.43M | 38.07M | 38.35M | 30.18M |
| ResearchAndDevelopment | 36.57M | 32.13M | 31.74M | 23.82M |
| SellingGeneralAndAdministration | 5.86M | 5.94M | 6.62M | 6.36M |
| GeneralAndAdministrativeExpense | 5.86M | 5.94M | 6.62M | 6.36M |
| OtherGandA | 5.86M | 5.94M | 6.62M | 6.36M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 63.16M | 61.85M | 59.43M | 59.34M |
| ShareIssued | 63.16M | 61.85M | 59.43M | 59.34M |
| NetDebt | 91.11M | 46.08M | 21.24M | |
| TotalDebt | 106.25M | 71.79M | 39.87M | 29.06M |
| TangibleBookValue | -105.29M | -62.46M | -34.43M | 366.00K |
| InvestedCapital | 933.00K | 9.28M | 5.40M | 29.41M |
| WorkingCapital | -18.16M | 12.03M | 7.54M | 32.79M |
| NetTangibleAssets | -103.07M | -60.24M | -32.19M | 2.62M |
| CapitalLeaseObligations | 19.00K | 46.00K | 40.00K | 8.00K |
| CommonStockEquity | -105.29M | -62.46M | -34.43M | 366.00K |
| PreferredStockEquity | 2.22M | 2.22M | 2.23M | 2.25M |
| TotalCapitalization | -17.96M | 11.50M | 7.63M | 31.66M |
| TotalEquityGrossMinorityInterest | -103.07M | -60.24M | -32.19M | 2.62M |
| StockholdersEquity | -103.07M | -60.24M | -32.19M | 2.62M |
| RetainedEarnings | -401.57M | -354.37M | -309.57M | -270.69M |
| AdditionalPaidInCapital | 296.22M | 291.85M | 275.08M | 271.00M |
| CapitalStock | 2.29M | 2.28M | 2.29M | 2.31M |
| CommonStock | 62.00K | 61.00K | 59.00K | 59.00K |
| PreferredStock | 2.22M | 2.22M | 2.23M | 2.25M |
| TotalLiabilitiesNetMinorityInterest | 120.56M | 88.44M | 53.48M | 39.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 85.16M | 72.77M | 40.47M | 30.18M |
| OtherNonCurrentLiabilities | 20.00K | 66.00K | ||
| DerivativeProductLiabilities | 47.00K | 1.00M | 573.00K | 1.13M |
| LongTermDebtAndCapitalLeaseObligation | 85.11M | 71.74M | 39.83M | 29.05M |
| LongTermDebt | 85.11M | 71.74M | 39.83M | 29.05M |
| CurrentLiabilities | 35.41M | 15.68M | 13.01M | 9.03M |
| OtherCurrentLiabilities | 369.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 21.14M | 46.00K | 40.00K | 8.00K |
| CurrentCapitalLeaseObligation | 19.00K | 46.00K | 40.00K | 8.00K |
| CurrentDebt | 21.12M | |||
| OtherCurrentBorrowings | 21.12M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.52M | 1.13M | 973.00K | 728.00K |
| PayablesAndAccruedExpenses | 12.38M | 14.50M | 12.00M | 8.30M |
| CurrentAccruedExpenses | 6.66M | 8.01M | 8.04M | 6.43M |
| Payables | 5.72M | 6.49M | 3.95M | 1.87M |
| DividendsPayable | 63.00K | 63.00K | 64.00K | 65.00K |
| AccountsPayable | 5.66M | 6.43M | 3.89M | 1.80M |
| TotalAssets | 17.50M | 28.20M | 21.29M | 41.83M |
| TotalNonCurrentAssets | 243.00K | 490.00K | 733.00K | 7.00K |
| OtherNonCurrentAssets | 243.00K | 490.00K | 733.00K | 7.00K |
| NetPPE | 0.00 | 0.00 | 0.00 | 0.00 |
| AccumulatedDepreciation | -74.00K | -74.00K | -74.00K | -74.00K |
| GrossPPE | 74.00K | 74.00K | 74.00K | 74.00K |
| Leases | 2.00K | 2.00K | 2.00K | 2.00K |
| OtherProperties | 733.00K | 7.00K | ||
| MachineryFurnitureEquipment | 72.00K | 72.00K | 72.00K | 72.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 17.25M | 27.71M | 20.55M | 41.82M |
| OtherCurrentAssets | 2.13M | 2.05M | 1.96M | 2.17M |
| PrepaidAssets | 2.17M | |||
| CashCashEquivalentsAndShortTermInvestments | 15.12M | 25.66M | 18.59M | 39.65M |
| CashAndCashEquivalents | 15.12M | 25.66M | 18.59M | 39.65M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -41.77M | -32.97M | -31.06M | -24.31M |
| IssuanceOfDebt | 30.00M | 30.00M | 10.00M | 30.00M |
| IssuanceOfCapitalStock | 0.00 | 6.81M | ||
| EndCashPosition | 15.12M | 25.66M | 18.59M | 39.65M |
| BeginningCashPosition | 25.66M | 18.59M | 39.65M | 27.14M |
| ChangesInCash | -10.54M | 7.07M | -21.06M | 12.51M |
| FinancingCashFlow | 31.23M | 40.03M | 10.00M | 36.81M |
| CashFlowFromContinuingFinancingActivities | 31.23M | 40.03M | 10.00M | 36.81M |
| ProceedsFromStockOptionExercised | 1.23M | 10.03M | 0.00 | |
| NetCommonStockIssuance | 0.00 | 6.81M | ||
| CommonStockIssuance | 0.00 | 6.81M | ||
| NetIssuancePaymentsOfDebt | 30.00M | 30.00M | 10.00M | 30.00M |
| NetLongTermDebtIssuance | 30.00M | 30.00M | 10.00M | 30.00M |
| LongTermDebtIssuance | 30.00M | 30.00M | 10.00M | 30.00M |
| InvestingCashFlow | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingCashFlow | -41.77M | -32.97M | -31.06M | -24.31M |
| CashFlowFromContinuingOperatingActivities | -41.77M | -32.97M | -31.06M | -24.31M |
| ChangeInWorkingCapital | 2.28M | 4.68M | 4.97M | 3.96M |
| ChangeInPayablesAndAccruedExpense | 2.37M | 4.77M | 4.87M | 3.89M |
| ChangeInAccruedExpense | 4.44M | 2.10M | 623.00K | 206.00K |
| ChangeInInterestPayable | 4.44M | 2.10M | 623.00K | 206.00K |
| ChangeInPayable | -2.07M | 2.67M | 4.24M | 3.69M |
| ChangeInAccountPayable | -2.07M | 2.67M | 4.24M | 3.69M |
| ChangeInPrepaidAssets | -82.00K | -90.00K | 101.00K | 65.00K |
| OtherNonCashItems | 1.10M | 697.00K | 410.00K | 283.00K |
| StockBasedCompensation | 2.45M | 2.26M | 2.87M | 2.08M |
| DepreciationAmortizationDepletion | 37.00K | 33.00K | 32.00K | 41.00K |
| DepreciationAndAmortization | 37.00K | 33.00K | 32.00K | 41.00K |
| Depreciation | 37.00K | 33.00K | 32.00K | 41.00K |
| OperatingGainsLosses | -588.00K | 432.00K | -557.00K | -138.00K |
| GainLossOnInvestmentSecurities | -588.00K | 432.00K | -557.00K | -138.00K |
| NetIncomeFromContinuingOperations | -47.05M | -41.07M | -38.78M | -30.53M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GALT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|